EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP‐1RA in CHB and T2DM Patients

Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim iD, Jin-Ha Yoon

Liver International · 2025-05 · 45 (5)

DOI: 10.1111/liv.70060 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Liver International, online erschienen am 21.04.2025. Verfasst von Byungyoon Yun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Research Foundation of Korea, the National Research Foundation of Korea, the Korea Government (MSIT).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The prevalence of diabetes is increasing among chronic hepatitis B (CHB) patients. However, the relative efficacy of sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) or dipeptidyl peptidase‐4 inhibitors (DPP4i), compared with glucagon‐like peptide‐1 receptor agonists (GLP‐1RA), among such at‐risk populations remains unclear in terms of reducing liver‐related events (LRE).

Methods

Using a nationwide database (2019–2022), we identified CHB patients with diabetes (age ≥ 40) and established two new‐user cohorts: SGLT2i vs. GLP‐1RA and DPP4i vs. GLP‐1RA. LREs included hepatocellular carcinoma, cirrhosis, liver transplantation and liver‐related mortality. For appropriate balancing, propensity score matching (PSM) was performed for each cohort. Multivariate Cox regression models were used to estimate LRE risk with adjusted hazard ratios (aHR) and 95% confidence intervals (CI).

Results

Propensity score matching provided two separate cohorts: (1) SGLT2i ( n = 2297) vs. GLP‐1RA ( n = 461) and (2) DPP4i ( n = 803) vs. GLP‐1RA ( n = 165) users. The LREs risk was similar across each comparison, with aHRs of 0.82 (95% CI 0.49–1.37) for GLP‐1RA (vs. SGLT2i) and 0.93 (95% CI 0.41–2.07) for GLP‐1RA (vs. DPP4i), indicating no significant differences. Subgroup analyses showed a trend favouring GLP‐1RA over SGLT2i in females, obese individuals, antiviral therapy (AVT) users, those with diabetes complications, longer diabetes duration and physically active individuals. Compared with DPP4i, the trend was observed in AVT users and those with a shorter diabetes duration, though none were statistically significant.

Conclusion

Overall LRE risk was comparable between SGLT2i or DPP4i vs. GLP‐1RA users. Further prospective studies are required to identify who can benefit from specific medication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsHepatitis B, ChronicHumansFemaleMaleMiddle AgedPropensity ScoreAgedAdultLiver CirrhosisLiver TransplantationLiver NeoplasmsCarcinoma, Hepatocellular

Stichwörter der Autor:innen

liver‐related eventsnationwide studynew user cohortoral antidiabetic drugspropensity score matching

Substanzen

Sodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • The Institute for Occupational Health, Yonsei University College of Medicine, Seoul, Korea.
  • The Institute for Innovation in Digital Healthcare, Yonsei University Health System, Seoul, Korea.
  • Department of Public Health, Graduate School, Yonsei University, Seoul, Korea.
  • Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.

ORCID-Profile: Beom Kyung Kim

Förderung

  • National Research Foundation of Korea
  • the National Research Foundation of Korea
  • the Korea Government (MSIT)
  • Ministry of Science and ICT, South Korea

Zitieren

APA

Yun, B., Oh, J., Park, H., Lee, J., Kim, B. K., & Yoon, J. H. (2025). Comparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP‐1RA in CHB and T2DM Patients. Liver International, 45(5). https://doi.org/10.1111/liv.70060

Vancouver

Yun B, Oh J, Park H, Lee J, Kim BK, Yoon JH. Comparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP‐1RA in CHB and T2DM Patients. Liver International. 2025;45(5). doi:10.1111/liv.70060

BibTeX
@article{Yun2025,
  author = {Yun, Byungyoon and Oh, Juyeon and Park, Heejoo and Lee, Jian and Kim, Beom Kyung and Yoon, Jin-Ha},
  title = {Comparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP‐1RA in CHB and T2DM Patients},
  journal = {Liver International},
  year = {2025},
  volume = {45},
  number = {5},
  doi = {10.1111/liv.70060}
}
Kostenlos starten →